Fulcrum Therapeutics (NASDAQ:FULC) vs. Lakeshore Biopharma (NASDAQ:LSB) Financial Survey

Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Risk & Volatility

Fulcrum Therapeutics has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Fulcrum Therapeutics and Lakeshore Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	1	3	3	1	2.50
Lakeshore Biopharma	0	0	0	0	0.00

Fulcrum Therapeutics presently has a consensus price target of $6.29, indicating a potential downside of 13.30%. Given Fulcrum Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Fulcrum Therapeutics is more favorable than Lakeshore Biopharma.

Insider & Institutional Ownership

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Fulcrum Therapeutics and Lakeshore Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80.00 million	4.89	-$97.33 million	($0.07)	-103.57
Lakeshore Biopharma	$672.27 million	0.01	-$61.09 million	N/A	N/A

Lakeshore Biopharma has higher revenue and earnings than Fulcrum Therapeutics.

Profitability

This table compares Fulcrum Therapeutics and Lakeshore Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-7.31%	-6.74%
Lakeshore Biopharma	N/A	N/A	N/A

Summary

Fulcrum Therapeutics beats Lakeshore Biopharma on 8 of the 12 factors compared between the two stocks.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Lakeshore Biopharma

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.